Commentary|Articles|March 31, 2026

Rising Rates, Screening Gaps, and Emerging Therapeutic Targets in CRC: Your Key Clinical Questions Answered

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

During colorectal cancer (CRC) awareness month, OncLive® sat down with Jeremy Kortmansky, MD, to discuss frequently asked questions about the complexities of CRC management and the rising incidence of CRC in young adults. The following FAQ, adapted from the conversation, provides clinical insights into potential risk factors for CRC in young adults, gaps in screening and early symptom identification contributing to this phenomenon, and the evolving landscape of molecularly targeted therapies in the space.

Related to this article